Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Kevin Conroy, Katherine Napier, David Thompson, and Roopwant Judge

Premium

Exact Sciences' shareholders have re-elected three members of its board of directors, including company President and CEO Kevin Conroy, as well as Katherine Napier, and David Thompson.

Napier, who has been a director since 2009, spent over two decades at Procter and Gamble, where she was a GM of the firm's North American pharmaceutical business.

Thompson, who spent 30 years at Abbott Laboratories and served as VP and president of Abbott's Laboratories Diagnostics Division, has been a director at Exact Sciences since 2010.


Proteomics International announced this week that it has appointed Roopwant Judge to a business development role with the company.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.